

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

# **Occurrence and distribution of extended spectrum $\beta$ -lactamase and AmpC- $\beta$ -lactamase-producing Enterobacteriaceae and methicillin resistant *Staphylococcus aureus* in companion animals in New Zealand**

A thesis presented in partial fulfilment of the requirements for the degree of

**Doctor of Philosophy**

In

Microbiology

**Institute of Veterinary, Animal and Biomedical Sciences**

**Massey University**

**Palmerston North, New Zealand**

**Ali Karkaba**

**2017**



By James Gallagher  
Health editor, BBC News website

© 19 November 2015 | Health



NEWS NOVEMBER 20, 2012 THE ECONOMIST

# Science under siege from superbug

MICHELLE DUFF

ANTI-COAGULATION aspirin can harm the heart (front left) or the lungs (front right). A controversial finding in a study of 10,000 patients is enough to bring down its approval in the United States — at least in the short term. “It’s a little unclear, you can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company.

“You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company. “You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company. “You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company. “You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company.

“You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company. “You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company. “You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company. “You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company.

“You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company. “You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company. “You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company. “You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company.

“You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company. “You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company. “You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company. “You can’t deny it,” says the aspirin’s maker, Bristol-Myers Squibb, the Power Glivec company.

## SUPERBUGS ON THE RISE

Total number of patients affected. The MRSA figure includes patients who died (see text)

### ESBL (extended spectrum beta lactamase)

Year	Number of patients
2006	117
2007	426
2008	317
2009	396
2010	323
2011	323

### MRSA (methicillin-resistant staphylococcus aureus)

Year	Number of patients
2006	130
2007	184
2008	11
2009	30
2010	101
2011	16

### ESBL (extended spectrum beta lactamase)

Year	Number of patients
2006	117
2007	426
2008	317
2009	396
2010	323
2011	323

ESBL (extended spectrum beta lactamase) is a type of bacteria that is resistant to many antibiotics. It is found in both humans and animals. The chart shows a significant increase in the number of patients affected by ESBL from 2006 to 2011.

MRSA (methicillin-resistant staphylococcus aureus) is a type of bacteria that is resistant to many antibiotics. It is found in both humans and animals. The chart shows a significant increase in the number of patients affected by MRSA from 2006 to 2011.

ESBL (extended spectrum beta lactamase) is a type of bacteria that is resistant to many antibiotics. It is found in both humans and animals. The chart shows a significant increase in the number of patients affected by ESBL from 2006 to 2011.

MRSA (methicillin-resistant staphylococcus aureus) is a type of bacteria that is resistant to many antibiotics. It is found in both humans and animals. The chart shows a significant increase in the number of patients affected by MRSA from 2006 to 2011.

**“The problem here is that science is on the edge, we are being challenged with something we don’t know how to prevent if it broke out.”**

Dr. Peter Salmon

ESBL (extended spectrum beta lactamase) is a type of bacteria that is resistant to many antibiotics. It is found in both humans and animals. The chart shows a significant increase in the number of patients affected by ESBL from 2006 to 2011.

MRSA (methicillin-resistant staphylococcus aureus) is a type of bacteria that is resistant to many antibiotics. It is found in both humans and animals. The chart shows a significant increase in the number of patients affected by MRSA from 2006 to 2011.

ESBL (extended spectrum beta lactamase) is a type of bacteria that is resistant to many antibiotics. It is found in both humans and animals. The chart shows a significant increase in the number of patients affected by ESBL from 2006 to 2011.

MRSA (methicillin-resistant staphylococcus aureus) is a type of bacteria that is resistant to many antibiotics. It is found in both humans and animals. The chart shows a significant increase in the number of patients affected by MRSA from 2006 to 2011.

ESBL (extended spectrum beta lactamase) is a type of bacteria that is resistant to many antibiotics. It is found in both humans and animals. The chart shows a significant increase in the number of patients affected by ESBL from 2006 to 2011.

MRSA (methicillin-resistant staphylococcus aureus) is a type of bacteria that is resistant to many antibiotics. It is found in both humans and animals. The chart shows a significant increase in the number of patients affected by MRSA from 2006 to 2011.

<http://www.stuff.co.nz/national/health/9418833/Science-under-siege-from-superbug>

iii

## Abstract

---

The increasing incidence of infections with extended spectrum-lactamase (ESBL)- and AmpC-producing Enterobacteriaceae, and methicillin-resistant *Staphylococcus aureus* (MRSA) in humans in the last decade is a matter of concern. There is a paucity of data on the incidence of infections with these bacteria in animals, partly because veterinary diagnostic laboratories do not routinely test for these organisms in clinical specimens. The carriage rate of these bacteria by companion animals is also unknown.

This PhD project aimed to investigate the occurrence of ESBL/AmpC-producing Enterobacteriaceae and MRSA in clinical specimens from animals in New Zealand, and examine the carriage of multidrug-resistant (MDR), ESBL/AmpC-*E. coli*, and MRSA in cats and dogs in Auckland.

The results of this project indicate that ESBL/AmpC-producing *E. coli* and MRSA cause clinical infections in companion animals in New Zealand. The circulation of these bacteria is likely to be posing therapeutic challenges to unaware veterinarians. The bacteria causing infections or carried by companion animals are genetically similar to those found in humans in New Zealand, raising public health concerns about the role of carrier animals as potential sources of zoonotic infections.

## General Introduction and overview of thesis

---

The relationship between humans and animals have changed, and pets are today considered an integral part of the family. However, this close proximity of pets is considered a potential hazard as a reservoir for antimicrobial resistant bacteria and potential zoonosis (Chomel 2011). Antimicrobial resistance is an emerging global problem, and New Zealand recognizes this threat in line with the rest of the world and is trying to reduce this burden using the 'One Health' approach (Gibbs 2014). This requires leadership and commitment from all sectors, in recognition that antimicrobial resistant bacteria abound in the different ecosystems shared by humans, food animals, and companion animals.

The widespread use and misuse of antimicrobials is considered the main factor driving the increase of antimicrobial resistance and the accelerated evolution and emergence of multi-drug resistant organisms that are difficult-to-treat (Aleksun and Levy 2006; Johns *et al.* 2012; Guo *et al.* 2015). The emergence of resistance to multiple drugs in animals decreases the efficacy of antimicrobials for the treatment of bacterial infections and may increase the rate of zoonotic resistant organisms (Yamamoto *et al.* 2014). *Escherichia coli* and *Staphylococcus aureus* are two of the most commonly isolated antimicrobial resistant bacteria in humans and animals (Yamamoto *et al.* 2014). Several studies have reported similar antimicrobial resistance profiles and genetic makeup in *E. coli* and *S. aureus* isolates recovered from both clinically affected and healthy humans and pets (Johnson *et al.* 2008; Davis *et al.* 2015; Guo *et al.* 2015; Carvalho *et al.* 2016; Loncaric *et al.* 2016).

The acquisition of antimicrobial resistance occurs mainly through mutation at the antimicrobial target sites, or by transfer of resistance genes via mobile elements, such as plasmids. In particular, a number of clinically important antimicrobial resistance mechanisms are mediated by the production of extended spectrum  $\beta$ -lactamases (ESBLs) or AmpC  $\beta$ -lactamases in Gram-negative bacteria, and by target site modification in the Gram-positive species *Staphylococcus aureus* (methicillin resistant *Staphylococcus aureus*; MRSA). Production of  $\beta$ -lactamase enzymes by infecting bacteria is

associated with therapy failure of  $\beta$ -lactam antimicrobials, prolonged and recurrent infections, and sometimes mortality (Hordijk *et al.* 2013). Furthermore, bacteria producing these enzymes are often also resistant to other antimicrobial classes, further complicating treatment (Jacoby 2005; Monecke *et al.* 2011; Bush 2012).

In New Zealand, as elsewhere, the incidence of clinical infections with ESBL and AmpC producing Enterobacteriaceae, in particular *E. coli*, and with MRSA, has increased significantly in humans in the last decade (Dyet *et al.* 2014; Heffernan and Bakker 2016). However, there is a paucity of data on antimicrobial resistant bacteria isolated from animal species, which leads to difficulty in estimating the scale of the problem and its potential impact on animal and human health. Thus, the objective of this PhD project was to study the molecular epidemiology of ESBL/AmpC producing *E. coli* (ESBL/AmpC-E) and MRSA from companion animals in New Zealand.

The thesis starts with an overview of the literature on ESBL and AmpC producing bacteria and MRSA, their resistance mechanisms and the clinical significance of the infections in humans and animals (Chapter 1). This is followed by five observational epidemiological studies of ESBL and AmpC-producing bacteria and MRSA in companion animals (Chapters 2 – 6). The thesis was written in the form of individual publications; thus, some repetitions were inevitable, especially in the introduction sections of the different chapters. A pilot study aimed at selecting the optimal method for the isolation of ESBL/AmpC-E is reported in Appendix 1 and the raw data collected in this project is in the attached CD.

The first observational study (Chapter 2) was performed in co-operation with New Zealand veterinary diagnostic laboratories, with the aims of (1) establishing whether ESBL/AmpC-E are causing clinical infections in companion animals, and (2) genetically characterise the strains. This was

followed with an epidemiological study (





**MASSEY UNIVERSITY**  
GRADUATE RESEARCH SCHOOL

**STATEMENT OF CONTRIBUTION  
TO DOCTORAL THESIS CONTAINING PUBLICATIONS**

(To appear at the end of each thesis chapter/section/appendix submitted as an article/paper or collected as an appendix at the end of the thesis)

We, the candidate and the candidate's Principal Supervisor, certify that all co-authors have consented to their work being included in the thesis and they have accepted the candidate's contribution as indicated below in the *Statement of Originality*.

Name of Candidate: Ali Karkaba

Name/Title of Principal Supervisor: Alex Grinberg

Name of Published Research Output and full reference:

Karkaba, A. Grinberg, J. Benschop, E. Pleydell (2016). Characterisation of extended spectrum  $\beta$ -lactamase and AmpC  $\beta$ -lactamase-producing Enterobacteriaceae isolated from companion animals in New Zealand. New Zealand Veterinary Journal

In which Chapter is the Published Work: Chapter 2

Please indicate either:

- The percentage of the Published Work that was contributed by the candidate:

and / or

- Describe the contribution that the candidate has made to the Published Work:

The candidate designed the study, collected the samples and processed them at Massey University. He wrote the first draft of the paper and responded to the co-authors' feedback and qualified as first and correspondent author.

Ali Karkaba  
Digitally signed by Ali Karkaba  
Date: 2017.03.02 17:13:35  
+13'00'

Candidate's Signature

02/03/2017

Date

Alex Grinberg  
Digitally signed by Alex Grinberg  
Date: 2017.03.03 10:55:04  
+13'00'

Principal Supervisor's signature

03/03/2017

Date

Chapter 3) performed in co-operation with veterinary practices in Auckland, to estimate the faecal carriage of these bacteria by cats and dogs (



**MASSEY UNIVERSITY**  
GRADUATE RESEARCH SCHOOL

**STATEMENT OF CONTRIBUTION  
TO DOCTORAL THESIS CONTAINING PUBLICATIONS**

(To appear at the end of each thesis chapter/section/appendix submitted as an article/paper or collected as an appendix at the end of the thesis)

We, the candidate and the candidate's Principal Supervisor, certify that all co-authors have consented to their work being included in the thesis and they have accepted the candidate's contribution as indicated below in the *Statement of Originality*.

Name of Candidate: Ali Karkaba

Name/Title of Principal Supervisor: Alex Grinberg

Name of Published Research Output and full reference:

Karkaba, A. Grinberg, J. Benschop, E. Pleydell (2016). Characterisation of extended spectrum  $\beta$ -lactamase and AmpC  $\beta$ -lactamase-producing Enterobacteriaceae isolated from companion animals in New Zealand. New Zealand Veterinary Journal

In which Chapter is the Published Work: Chapter 2

Please indicate either:

- The percentage of the Published Work that was contributed by the candidate:

and / or

- Describe the contribution that the candidate has made to the Published Work:

The candidate designed the study, collected the samples and processed them at Massey University. He wrote the first draft of the paper and responded to the co-authors' feedback and qualified as first and correspondent author.

Ali Karkaba  
Digitally signed by Ali Karkaba  
Date: 2017.03.02 17:13:35  
+13'00'

Candidate's Signature

02/03/2017

Date

Alex Grinberg  
Digitally signed by Alex Grinberg  
Date: 2017.03.03 10:55:04  
+13'00'

Principal Supervisor's signature

03/03/2017

Date

[Chapter 3](#)). Chapter 4 assessed the risk factors associated with the faecal carriage by cats and dogs. Phenotypic and molecular analysis of the strains

reported in Chapter 2 and



**MASSEY UNIVERSITY**  
GRADUATE RESEARCH SCHOOL

**STATEMENT OF CONTRIBUTION  
TO DOCTORAL THESIS CONTAINING PUBLICATIONS**

(To appear at the end of each thesis chapter/section/appendix submitted as an article/paper or collected as an appendix at the end of the thesis)

We, the candidate and the candidate's Principal Supervisor, certify that all co-authors have consented to their work being included in the thesis and they have accepted the candidate's contribution as indicated below in the *Statement of Originality*.

Name of Candidate: **Ali Karkaba**

Name/Title of Principal Supervisor: **Alex Grinberg**

Name of Published Research Output and full reference:

Karkaba, A. Grinberg, J. Benschop, E. Pleydell (2016). Characterisation of extended spectrum  $\beta$ -lactamase and AmpC  $\beta$ -lactamase-producing Enterobacteriaceae isolated from companion animals in New Zealand. *New Zealand Veterinary Journal*

In which Chapter is the Published Work: **Chapter 2**

Please indicate either:

- The percentage of the Published Work that was contributed by the candidate:  and / or
- Describe the contribution that the candidate has made to the Published Work:

The candidate designed the study, collected the samples and processed them at Massey University. He wrote the first draft of the paper and responded to the co-authors' feedback and qualified as first and correspondent author.

**Ali Karkaba** Digitally signed by Ali Karkaba  
Date: 2017.03.02 17:13:35  
+13'00'  
\_\_\_\_\_  
Candidate's Signature

**02/03/2017**  
\_\_\_\_\_  
Date

**Alex Grinberg** Digitally signed by Alex Grinberg  
Date: 2017.03.03 10:55:04  
+13'00'  
\_\_\_\_\_  
Principal Supervisor's signature

**03/03/2017**  
\_\_\_\_\_  
Date

Chapter 3 inform Chapter 5, which assesses the clonal relatedness of ESBL/AmpC-E across faecal carriage and disease.

The last study (Chapter 6) characterised MRSA identified from clinical infections in animals in New Zealand, and estimated the prevalence of MRSA carriage in dogs and cats in Auckland.

All the studies in this thesis were conducted between June 2012 and June 2013. Chapter 2 and Chapter 6 have been published in condensed form in refereed journals and were also presented at conferences.

### **Declaration**

This thesis contains no material that has been accepted for another degree or diploma at Massey University or any other institution. To the best of my knowledge, no material previously published or written by another person has been used, except where due acknowledgment has been made in text.



## **Acknowledgements**

Gratitude perpetuates blessings. Words are not enough to show my gratitude for a lot of people that helped me during this journey. I would like to thank my main supervisor Alex Grinberg for his mentoring, patience, encouragement, endless hours of meetings, supervision and support. Besides my main supervisor, I would like to thank the PhD co-supervisors, Eve Pleydell, that had a major role at the beginning of this PhD studies and left for another job; Kate Hills' role at the beginning of the studies that also left; lastly but not least, Jackie Benschop that took the burden of the co-supervision, and the important role in mentoring, guidance and support during the PhD studies.

I would like thank a number of people who assisted me in the laboratory and guided me in some techniques, Kristen Gedye and Niluka Velathanthiri. To New Zealand Veterinary Pathology for their time and expertise and for donating the isolates for this study, in particular Ian for his support and contribution.

Lastly, I would like to thank my colleagues; Julanda Al Mawly who welcomed me and supported me with kind words during my first year; Emilie Vallee for Epidemiology tips and support; office mates and friends: Jose Solis, Gustavo Chamon, Felipe Lembye, Daniela Tapia Escarate, Kandarp Patel, Sharini Somasiri, Masako Wada, Antoine Nohra, Doris Adeyanka, and Ali Alhajouj.

Heartfelt thanks to my family that without them I wouldn't be here.

## List of contents

	i
Abstract	iv
General Introduction and overview of thesis	v
Declaration	xv
Acknowledgements	xvi
List of contents	xvii
List of Tables	xxi
List of Figures	xxiii
List of Abbreviations	xxiv
List of publications	xxv
Chapter 1: Infections with extended-spectrum $\beta$ -lactamase and AmpC $\beta$ -lactamase-producing Enterobacteriaceae and methicillin resistant <i>Staphylococcus aureus</i> in companion animals – an overview	1
Introduction	1
1.1 Enterobacteriaceae and <i>S. aureus</i> resistance to $\beta$ -lactams-brief overview	2
1.1.1 Extended spectrum $\beta$ -lactamase-producing Enterobacteriaceae	3
1.1.2 AmpC $\beta$ -lactamase-producing Enterobacteriaceae	6
1.1.3 Methicillin resistant <i>Staphylococcus aureus</i> (MRSA)	8
1.2 Epidemiology of infections with ESBL/AmpC-producing Enterobacteriaceae and MRSA in companion animals - general considerations	12
1.2.1 Studies of ESBL/AmpC-producing Enterobacteriaceae in companion animals	13
1.2.2 Studies of MRSA in companion animals	17
1.3 Interspecies transmission of ESBL/AmpC producing Enterobacteriaceae and MRSA, and associated public health concerns	19
1.3.1 Interspecies transmission of ESBL/AmpC producing Enterobacteriaceae	20
1.3.2 Interspecies transmission of MRSA	21
1.4 Population genetics	25
1.4.1 <i>Escherichia coli</i>	25
1.4.2 <i>Staphylococcus aureus</i>	27
1.5 Concluding Remarks	29
Chapter 2: Characterisation of extended spectrum $\beta$ -lactamase and AmpC $\beta$ -lactamase-producing Enterobacteriaceae isolated from companion animals in New Zealand	31
Preamble	31
Summary	31
2.1 Introduction	33
2.2 Materials and methods	34
	xvii

2.2.1	Collection of Enterobacteriaceae isolates	34
2.2.2	Bacterial identification and antimicrobial susceptibility testing	35
2.2.3	Genotyping	37
2.2.4	Data analysis	38
2.3	Results	39
2.3.1	Identified bacterial species	39
2.3.2	Antimicrobial susceptibility test results	40
2.3.3	Distribution of ESBL and AmpC genes	41
2.4	Discussion	47
2.5	Conclusion	50
2.6	Supplementary material	51
Chapter 3: Cross sectional study of prevalence of faecal carriage of multi-drug resistant, and extended spectrum $\beta$ -lactamase and AmpC $\beta$ -lactamase-producing <i>Escherichia coli</i> in cats and dogs in the Auckland region		58
	Preamble	58
	Summary	58
3.1	Introduction	59
3.2	Materials and methods	62
3.2.1	Study population and recruitment of veterinary clinics	62
3.2.2	Sample collection	63
3.2.3	Isolation of MDR-E and ESBL/AmpC-E and genotyping of the isolates	64
3.2.4	Data Handling and Statistical Analysis	64
3.2.5	Ethical Approval	65
3.3	Results	65
3.3.1	Characteristics of the study population	65
3.3.2	Isolation of MDR-E and ESBL/AmpC-E	65
3.3.3	Molecular Characterisation of MDR-E and ESBL/AmpC positive-E	67
3.3.4	Multilocus sequence typing (MLST)	68
3.4	Discussion	71
3.5	Conclusions	74
Chapter 4: Risk factors for faecal carriage of multidrug resistant, extended spectrum $\beta$ -lactamase and AmpC $\beta$ -lactamase-producing <i>Escherichia coli</i> in cats and dogs in Auckland, New Zealand		86
	Preamble	86
	Summary	86
4.1	Introduction	87
4.2	Materials and methods	93
4.2.1	Data collection, sample processing and questionnaire analysis	93

4.2.2	Multivariable statistical modeling	102
4.3	Results	104
4.3.1	Prevalence of MDR-E and ESBL/AmpC-E	104
4.3.2	Data analysis	104
4.3.3	Analysis of results:	107
4.4	Discussion	109
4.5	Conclusion	115
4.6	Supplementary Material	127
Chapter 5: Genetic comparison of extended-spectrum $\beta$ -Lactamase and AmpC-producing <i>Escherichia coli</i> strains from faecal carriage and clinical infections in cats and dogs in New Zealand		130
	Preamble	130
	Summary	133
5.1	Introduction	134
5.2	Materials and methods	142
5.2.1	<i>E. coli</i> isolates from faeces and clinical samples	142
5.2.2	Data analysis	145
5.3	Results	145
5.3.1	Antimicrobial susceptibility profiles of analysed <i>E. coli</i> isolates	148
5.3.2	Genotyping results	149
5.4	Discussion	154
5.5	Conclusion	156
Chapter 6: Characterisation of methicillin resistant <i>Staphylococcus aureus</i> isolated from animals in New Zealand, 2012–2013, and MRSA colonisation in cats and dogs in Auckland		157
	Preamble	158
	Summary	161
6.1	Introduction	162
6.2	Materials and methods	164
6.2.1	Study population and phenotypic MRSA detection	164
6.2.2	MRSA strain-type definition and nomenclature	170
6.2.3	Genotyping of MRSA isolates	170
6.2.4	Data Analysis	171
6.3	Results	172
6.3.1	Characteristics and antimicrobial susceptibility of <i>S. aureus</i> clinical isolates submitted by diagnostic laboratories	172
6.3.2	Characteristics of the MRSA clinical isolates	172
6.3.3	Prevalence of MRSA in the samples from cats and dogs	174
6.4	Discussion	176

6.5	Conclusion	178
6.6	Supplementary Material	179
Chapter 7: General Discussion		188
References		207
Appendix 1: Comparison between different culture methods for the isolation of extended spectrum $\beta$ -lactamase and AmpC $\beta$ -lactamase producing <i>Escherichia coli</i> from faeces of cats and dogs		234
Materials and Methods		240
Collection of faecal samples		240
Laboratory methods		241
Results		248
Comparison of isolation of AMR-E between methods		248
Detection of ESBL/AmpC-E by the different culture methods		249
Molecular characterisation of ESBL/AmpC-positive-E		252
Comparison of phenotypes and genotypes of ESBL/AmpC-E		254
Cost and utility considerations		255
Discussion and conclusions		255

## List of Tables

Table 2.1: Number (%) of Enterobacteriaceae isolates (n=115) sourced from companion animals and submitted by seven veterinary diagnostic laboratories between June 2012 and June 2013 that met selection criteria <sup>a</sup> by bacterial species and source material.....	40
Table 2.2: The number and proportion of Enterobacteriaceae isolates resistant to commonly used antibiotics sourced from companion animals between June 2012 and June 2013 that met selection criteria <sup>a</sup> , categorised by $\beta$ -lactamase genotype	41
Table 2.3: Characteristics of ESBL and/or AmpC-producing Enterobacteriaceae isolates (n=60).....	44
Table S 2.1: Details of the mutations in the ampC promoter sequences in the nine bla <sub>AmpC</sub> -negative <i>E. coli</i> isolates displaying the AmpC phenotype .....	51
Table S 2.2: Multilocus sequence type allele designation of the five new sequence types found in this study.....	51
Table S 2.3: Antibigrams and details of the 115 Enterobacteriaceae and 12 fully susceptible <i>E. coli</i> isolates used in this study.....	52
Table 3.1: Number of <i>Escherichia coli</i> isolates isolated from faecal samples, classified by the resistance groups, obtained in a cross-sectional study of 586 cats and dogs in Auckland, New Zealand (confidence intervals were adjusted for clustering within clinics).....	66
Table 3.2: Antimicrobial susceptibility results of faeces and of <i>Escherichia coli</i> isolates obtained in a cross-sectional survey of 586 cats and dogs in Auckland, New Zealand. ....	66
Table 3.3: ESBL and AmpC $\beta$ -lactamase genes of the 43 <i>Escherichia coli</i> isolates included in the study.....	67
Table 3.4: Classification of the MDR/ESBL/AmpC-E and 14 non-MDR/ESBL/AmpC-E isolates found in this study according to their multilocus sequence types (ST) and clonal complexes, as defined in the Warwick database .....	70
Table S 3.1: Details of the 43 characterised MDR-E, and ESBL/AmpC-E and 14 Non-MDR/ESBL/AmpC-E.....	83
Table 4.1: Univariate screening of the variables elicited by the questionnaire against the binary outcome of faecal carriage (yes/no) of extended spectrum $\beta$ -lactamase (ESBL) and AmpC- $\beta$ -lactamase-producing <i>Escherichia coli</i> , with the clinic as random effect .....	116
Table 4.2: Univariate screening of the variables elicited by the questionnaire against the binary outcome of faecal carriage (yes/no) of multi drug resistant (MDR), and/or extended spectrum $\beta$ -lactamase (ESBL) and/or AmpC- $\beta$ -lactamase-producing <i>Escherichia coli</i> , with the clinic as random effect .....	118
Table 4.3: Variables associated with faecal carriage of ESBL/AmpC producing <i>E. coli</i> in the final multivariable model with random clinic effect .....	119
Table 4.4: Variables associated with faecal carriage of MDR and/or ESBL and/or AmpC producing <i>E. coli</i> in the final multivariable model with random clinic effect	120

Table S 4.1: Characteristics of 572 cats and dogs for which completed questionnaires were available.....	127
Table S 4.2: Breeds of 572 cats and dogs for which completed questionnaires were available.....	127
Table S 4.3: Household demographics of the sampled animals.....	127
Table S 4.4: Types of antimicrobial prescriptions in cats and dogs in the 6 month preceding the sampling.....	128
Table S 4.5: List of antimicrobials administered to cats and dogs in the last six months.....	128
Table S 4.6 : Frequency of hospitalisation and/or surgery six months prior to sampling, among the sampled cats and dogs.....	129
Table S 4.7: Information about animals living in the same house over the last 6 months.....	129
Table S 4.8: Information about people living in the same house over the last 6 months.....	129

Table 5.1: Classification of 81 <i>Escherichia coli</i> isolates included in this chapter according to their $\beta$ -lactamase production.....	149
Table 5.2: The antimicrobial susceptibility testing results of the 81 <i>Escherichia coli</i> isolates analysed in this study; No (%).....	149
Table 5.3: $\beta$ -lactamase genes identified in <i>E. coli</i> isolates.....	150
Table 5.4: Sequence types (STs) of the <i>E. coli</i> isolates included in this study categorised by multi drug resistance (MDR) and $\beta$ -lactamase production. ....	151
Table 5.5: <i>E. coli</i> sequence types (STs) identified in ESBL/AmpC-E (both faecal and clinical isolates).....	152

Table 6.1: Details of the sources of eight methicillin resistant <i>Staphylococcus aureus</i> isolates submitted by veterinary diagnostic laboratories in New Zealand between June 2012 and June 2013.....	174
Table 6.2: In vitro antimicrobial susceptibility and molecular characterisation of the eight-methicillin resistant <i>Staphylococcus aureus</i> isolates isolated by veterinary diagnostic laboratories in New Zealand between June 2012 and June 2013.....	175

Table S 6.1 :Summary of the DNA microarray and spa results of the MRSA isolates.....	179
--	-----

Table A.1: Primers used for ESBL/AmpC detection by PCR in <i>E. coli</i> isolates .....	247
Table A.2: The antimicrobial susceptibility test results of faecal specimens in stage 1 with results of the confirmed <i>Escherichia coli</i> isolates in stage 2, stratified by microbiological method used .....	250
Table A.3: Antimicrobial resistance patterns of the 15 <i>Escherichia coli</i> isolates detected by method M1 .....	251
Table A.4: The antimicrobial susceptibility test results of the faecal specimens and <i>Escherichia coli</i> isolates from hospitalised and non-hospitalised animals using M1 method.....	251
Table A.5: Antimicrobial resistance profiles of ESBL/AmpC-producing <i>E. coli</i> isolates and $\beta$ -lactamase genes carried on plasmids of these isolates .....	253
Table A.6: Maximum and minimum costs/specimen and duration of processing the specimens according to the protocol chosen.....	255

## List of Figures

Figure 2.1: Rarefaction curves for multilocus sequence types of <i>Escherichia coli</i> isolates sourced from companion animals in New Zealand between June 2012 and June 2013 carrying extended spectrum $\beta$ -lactamase (blue line), plasmid-encoded AmpC $\beta$ -lactamase (green line) genes, or a chromosomal ampC mutation (red line), or that did not carry those genes (black line). The shaded areas around the curves represent 95% CI. ....	45
Figure 2.2: Minimum spanning tree of the multilocus sequence types (ST) of 89 <i>Escherichia coli</i> isolates sourced from companion animals in New Zealand between June 2012 and June 2013. ....	46
Figure 3.1: Minimum spanning tree showing the associations between the different <i>E. coli</i> multilocus genotypes (ST) found in this study. ....	69
Figure 4.1: Caterpillar plot of random clinic effect in the final model faecal carriage of ESBL and/or AmpC-E in cats and dogs. The symbols on the y-axis are the anonymous identifier codes of the clinics. ....	121
Figure 4.2: Caterpillar plot of random clinic effect in the final model faecal carriage of MDR-E and/or ESBL and/or AmpC-E in cats and dogs. The symbols on the y-axis are the anonymous identifier codes of the clinics. ....	122
Figure 4.3: Caterpillar plot of random clinic effect of final model faecal carriage of ESBL/AmpC-E in cats. The symbols on the y-axis are anonymous identifier codes of the clinics. ....	123
Figure 4.4: Caterpillar plot of random clinic effect of final model faecal carriage of MDR/ESBL/AmpC-E in cats. The symbols on the y-axis are anonymous identifier codes of the clinics. ....	124
Figure 4.5: Caterpillar plot of random clinic effect in the final model of the risk of faecal carriage of ESBL/AmpC-E in dogs. The symbols on the y-axis are anonymous identifier codes of the clinics. ....	125
Figure 4.6: Caterpillar plot of random clinic effect of final model of the risk of faecal carriage of MDR and/or ESBL and/or AmpC-E in dogs. The symbols on the y-axis are anonymous identifier codes of the clinics. ....	126
Figure 5.1: Rarefaction analysis of sequence types (STs) of ESBL/PAmpC-producing <i>E. coli</i> isolates. ....	151
Figure 5.2: Minimum spanning tree showing the associations between the different <i>E. coli</i> multilocus sequence types (ST) analysed in this study. ....	153
Figure A.1: Flow chart of the microbiologic analysis of faecal samples as per (M1) .....	243



## List of Abbreviations

<i>E. coli</i>	<i>Escherichia coli</i>
ESBL	Extended spectrum $\beta$ -lactamase
AmpC	AmpC $\beta$ -lactamase
ESBL-E	Extended spectrum $\beta$ -lactamase producing <i>E. coli</i>
AmpC-E	AmpC $\beta$ -lactamase producing <i>E. coli</i>
ESBL/AmpC-E	ESBL-E and/or AmpC-E
MLST	Multilocus sequence typing
ST	Sequence type
MALDI-TOF	Matrix assisted laser desorption/ionization time of flight
AMR	Antimicrobial resistant
MDR	Multi-drug resistant
ExPEC	Extra-intestinal pathogenic <i>E. coli</i>
HGT	Horizontal gene transfer
<i>S. aureus</i>	<i>Staphylococcus aureus</i>
MRSA	Methicillin resistant <i>Staphylococcus aureus</i>
SCC <sub>mec</sub>	Staphylococcal cassette chromosome

## List of publications

**Chapter 2:** Karkaba, A. Grinberg, K. E. Hill, J. Benschop (2017). Characterisation of methicillin resistant *Staphylococcus aureus* clinical isolates from animals in New Zealand, 2012–2013, and subclinical colonisation in dogs and cats in Auckland. *New Zealand Veterinary Journal*.

**Chapter 6:** Karkaba, A. Grinberg, J. Benschop, E. Pleydell (2017). Characterisation of extended spectrum  $\beta$ -lactamase and AmpC  $\beta$ -lactamase-producing Enterobacteriaceae isolated from companion animals in New Zealand. *New Zealand Veterinary Journal*.

A. Karkaba, K. Hill, J. Benschop, A. Grinberg and E. Pleydell (2013). Investigating strains of multidrug resistant Enterobacteriaceae and *Staphylococcus aureus* that are causing clinical infections in companion animals in New Zealand. *Proceedings of the New Zealand Veterinary Association Annual Conference*.

### Oral conference presentations:

A. Karkaba, K. Hill, J. Benschop, A. Grinberg and E. Pleydell (2013). Investigating the strains of multidrug resistant Enterobacteriaceae and *Staphylococcus aureus* that are causing clinical infections in companion animals in New Zealand. *Proceedings of 38th Annual WSAVA Congress*.

Karkaba, A., Hill, K., Benschop, J., Grinberg, A. and Pleydell, E. (2013). Comparison between five methods for isolation of multi drug-resistant *Escherichia coli* from faeces of hospitalized and non-hospitalized cats and dogs *Queenstown Molecular Biology Week and Webster Centre for Infectious Diseases Symposium: Of Microbes and Men – Translational Medical Microbiology in the 21st Century*. 29 – 30 August, 2013 Rydges Hotel, Queenstown, New Zealand

A. Karkaba, K. Hill, J. Benschop, A. Grinberg and E. Pleydell (2012). Investigating the strains of multidrug resistant Enterobacteriaceae causing clinical infections in companion animals in New Zealand. *Proceedings of First IDReC Science Symposium*.

